Phase 2 Study of YS110, a Recombinant Humanized Anti-CD26 Monoclonal Antibody, in Japanese Patients With Advanced Malignant Pleural Mesothelioma

Kazuhiko Nakagawa,Takashi Kijima,Morihito Okada,Masahiro Morise,Motoyasu Kato,Katsuya Hirano,Nobukazu Fujimoto,Mitsuhiro Takenoyama,Hiroshi Yokouchi,Yuichiro Ohe,Toyoaki Hida,Keisuke Aoe,Takumi Kishimoto, Masato Hirokawa, Hironori Matsuki,Yutaro Kaneko,Taketo Yamada,Chikao Morimoto,Masayuki Takeda

JTO Clinical and Research Reports（2021）

引用 5|浏览46

暂无评分

摘要

The 6-month disease control rate did not exceed the predefined threshold, but YS110 revealed modest efficacy in response rate as salvage therapy in difficult-to-treat patients with MPM. YS110 was generally well tolerated.

查看译文

关键词

YS110,Malignant mesothelioma,Phase 2,CD26,Japanese

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要